Provided by Tiger Trade Technology Pte. Ltd.

Tango Therapeutics Inc.

24.00
+1.305.73%
Pre-market: 23.93-0.0700-0.29%04:00 EDT
Volume:4.66M
Turnover:112.41M
Market Cap:4.06B
PE:-28.57
High:25.52
Open:22.99
Low:22.63
Close:22.70
52wk High:34.39
52wk Low:6.25
Shares:169.00M
Float Shares:142.96M
Volume Ratio:2.68
T/O Rate:3.26%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8400
EPS(LYR):-0.8746
ROE:-21.34%
ROA:-12.99%
PB:3.96
PE(LYR):-27.44

Loading ...

BUZZ-IDEAYA Biosciences drops on $300 mln equity raise

Reuters
·
Jun 09

U.S. RESEARCH ROUNDUP- Apple, Lennar, Toll Brothers

Reuters
·
Jun 09

Tango Therapeutics Inc : Leerink Partners Raises Target Price to $69 From $55

THOMSON REUTERS
·
Jun 09

Apple, SUNation Energy, Tango Therapeutics, Applied Digital And Cerebras Systems: Why These 5 Stocks Are On Investors' Radars Today

Benzinga
·
Jun 09

Tango Therapeutics launches USD 500 million common stock offering

Reuters
·
Jun 09

Tango Therapeutics Announces Proposed $500 Million Public Offering

THOMSON REUTERS
·
Jun 09

Top Midday Gainers

MT Newswires Live
·
Jun 09

Catanzaro Raises TNGX Price Target to $36, Reiterates Buy on Promising Vopimetostat/Daraxonrasib Data in Pancreatic Cancer

TIPRANKS
·
Jun 09

BUZZ-U.S. STOCKS ON THE MOVE -Tango Therapeutics, Intel, Ciena

Reuters
·
Jun 09

Tango Therapeutics Stock Soars 42% After 'Unprecedented' Data on Pancreatic Cancer Treatment -- Barrons.com

Dow Jones
·
Jun 09

Top Midday Stories: US Weighs Financial Stakes in AI Firms; Google, Nvidia Turn to Intel as TSMC Struggles With Demand

MT Newswires Live
·
Jun 08

Tango Therapeutics rises 32.1%

TIPRANKS
·
Jun 08

RBC Capital says Tango-Revolution data strengthens daraxonrasib’s PDAC position

TIPRANKS
·
Jun 08

Sector Update: Health Care

MT Newswires Live
·
Jun 08

Tango Therapeutics Shares Rise 45% Premarket After Co's Pancreatic Cancer Drug Combo Shows Promise in Study

THOMSON REUTERS
·
Jun 08

Tango Therapeutics' pancreatic cancer drug combo shows promise in study

Reuters
·
Jun 08

Tango Therapeutics Says Initial Results From Phase 1/2 Trial of Pancreatic Cancer Drug Candidate Showed Improvement in Survival Rate; Shares Rise Pre-Bell

MT Newswires Live
·
Jun 08

Tango Therapeutics announces data from study of vopimetostat, daraxonrasib

TIPRANKS
·
Jun 08

Tango Therapeutics - Vopimetostat Plus Daraxonrasib Generally Well Tolerated With No New Safety Signals

THOMSON REUTERS
·
Jun 08

Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer

THOMSON REUTERS
·
Jun 08